6533b827fe1ef96bd1285d83

RESEARCH PRODUCT

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group

Nadine Van RoyHuib N. CaronOlivier DelattreGudrun SchleiermacherGudrun SchleiermacherJohn LunecDasa JanousekJérôme CouturierAna P. BerbegallRosa NogueraMichael D. HogartyGian-paolo ToniniRuth LadensteinUlrike PötschgerTom MonclairEdward F. AttiyehJulie R. ParkKeith HolmesSue CohnAlexander ValentValérie CombaretBárbara MarquesAndrew D.j. PearsonVéronique MosseriIngrid PribillNicole GrossBruno De BernardiJean BénardMaja Beck-popovicPeter F. AmbrosVictoria CastelRaffaella DefferrariDeborah A. TweddleKlaus BeiskeInge M. AmbrosEvgenia GlogovaEva VillamónJean MichonKatia MazzoccoNick BownDominique Valteau-couanetTommy MartinssonPer KognerMarta Jeison

subject

OncologyCancer Researchmedicine.medical_specialtyGenomicsNeuroblastomaCogInternal medicineNeuroblastomaHumansMedicineProgression-free survivalSurvival rateNeoplasm StagingChromosome AberrationsClinical Trials as TopicN-Myc Proto-Oncogene ProteinValidation groupbusiness.industryChromosomes Human Pair 11Age FactorsGene AmplificationInfantORIGINAL REPORTSGenomicsPrognosismedicine.diseaseDiploidyProgression-Free SurvivalDoenças GenéticasSurvival RateOncologyPediatric OncologyChromosomes Human Pair 1Mycn amplificationNeoplasm stagingbusiness

description

Purpose: For localized, resectable neuroblastoma without MYCN amplification, surgery only is recommended even if incomplete. However, it is not known whether the genomic background of these tumors may influence outcome. Patients and methods: Diagnostic samples were obtained from 317 tumors, International Neuroblastoma Staging System stages 1/2A/2B, from 3 cohorts: Localized Neuroblastoma European Study Group I/II and Children's Oncology Group. Genomic data were analyzed using multi- and pangenomic techniques and fluorescence in-situ hybridization in 2 age groups (cutoff age, 18 months) and were quality controlled by the International Society of Pediatric Oncology European Neuroblastoma (SIOPEN) Biology Group. Results: Patients with stage 1 tumors had an excellent outcome (5-year event-free survival [EFS] ± standard deviation [SD], 95% ± 2%; 5-year overall survival [OS], 99% ± 1%). In contrast, patients with stage 2 tumors had a reduced EFS in both age groups (5-year EFS ± SD, 84% ± 3% in patients 18months. In older patients with SCA, a randomized trial of postoperative chemotherapy compared with observation alone may be indicated. Funded in part by Oesterreichische National Bank (Grant No. 13422), Wissenschaftsfonds FWF (Grant No. I 2799-B28), and Directorate-General V, European Commission (Grant No. SOC 98 201284 05F02), all to P.F.A.; and Instituto de Salud Carlos III (Grant No. PI17/01558) to R.N. info:eu-repo/semantics/publishedVersion

yearjournalcountryeditionlanguage
2020-11-01Journal of Clinical Oncology
https://doi.org/10.1200/jco.18.02132